Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.38 |
| ▸ | FCER2 | P06734 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 8/20 | 0.36 |
| ▸ | MMP3 | P08254 | 5/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709577 | 0.92 | MMP1 (0.38) | MMP1FCER2CTSCMMP2MMP3 | |
| SCHEMBL7322599 | 0.90 | MMP1 (0.39) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL9556170 | 0.89 | MMP1 (0.39) | MMP1FCER2CTSCMMP2MMP3 | |
| SCHEMBL9556449 | 0.86 | MMP1 (0.38) | MMP1FCER2CTSCMMP2MMP3 | |
| SCHEMBL5709641 | 0.80 | LTB4R (0.41) | — | |
| SCHEMBL5709644 | 0.77 | CTSS (0.35) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7322606 | 0.77 | CTSS (0.40) | MMP1FCER2MMP2MMP3MMP12 | |
| SCHEMBL6349082 | 0.76 | KDM4E (0.39) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6350291 | 0.74 | CTSS (0.36) | MMP1MMP2MMP3MMP9MMP14 | |
| SCHEMBL9556477 | 0.73 | UTS2R (0.36) | MMP1FCER2CTSCMMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-5229420-A | Renin inhibitor | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| US-4900746-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1990-02-13 | — | — | US | disclosed |
| WO-1990000051-A1 | ETHEREAL N-TERMINAL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | MMP1 636/4885FCER2 4005/4885CTSC 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.